Prelude Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Prelude Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	+67,857	New	+$413K	0.02%	874
2026 Q1	–	Sell	-28,832	Closed	-$326K	–	1350
2025 Q4	$326K	Hold	28,832	–	–	0.02%	752
2025 Q3	$265K	Sell	28,832 -114,297	-80%	-$827K	0.02%	789
2025 Q2	$985K	Sell	143,129 -49,078	-26%	-$263K	0.1%	264
2025 Q1	$554K	Buy	192,207 +106,122	+123%	+$390K	0.04%	472
2024 Q4	$405K	Buy	86,085 +62,985	+273%	+$232K	0.03%	668
2024 Q3	$82.5K	Sell	23,100 -5,000	-18%	-$37.1K	0.01%	1176
2024 Q2	$174K	Buy	+28,100	New	+$213K	0.01%	1030
2023 Q3	–	Sell	-11,171	Closed	-$36.9K	–	1211
2023 Q2	$36.9K	Buy	+11,171	New	+$32.8K	﹤0.01%	990
2020 Q3	–	Sell	-6,073	Closed	-$111K	–	2013
2020 Q2	$111K	Buy	+6,073	New	+$95.6K	0.01%	917

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's FULC Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 67,857 shares worth $248K. The stake represents 0.02% of the portfolio and ranks #874 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in FULC as recently as Q4 2025.

Prelude Capital Management first reported a position in FULC in Q2 2020 and has held it in 10 quarters since. The position peaked at $985K in Q2 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Prelude Capital Management held 67,857 shares of Fulcrum Therapeutics worth $248K as of Q2 2026.
Fulcrum Therapeutics was a new Prelude Capital Management position in Q2 2026.
Fulcrum Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #874 holding.
Prelude Capital Management first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 10 quarters since.
Prelude Capital Management's Fulcrum Therapeutics position peaked at $985K in Q2 2025.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.